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Isotretinoin, most often recognized by the brand name Accutane, is regarded by 
many patients and prescribers as the miracle cure for acne. Its unsurpassed efficacy is 
paired with serious risk of adverse events and birth defects, which poses ethical questions 
regarding its safety and necessity. Its regulatory history established precedent in Food 
and Drug Administration Risk Evaluation and Mitigation Strategies and brought 
awareness to the sharp dangers of teratogenic drug use.  
This medication came as a breakthrough solution to patients that suffered years of 
unsuccessful regimens for the treatment of acne vulgaris. Some question the risk-benefit 
evaluation of such a toxic drug for acne. It was noted in Archives of Family Medicine 
that “although acne is not a life-threatening disease, it has significant physical and 
psychological ramifications such as permanent scarring, poor self-image, social 
inhibition, depression and anxiety” (Thiboutot). Significant health implications press the 
need for such an effective drug. Accutane and isotretinoin generic drugs have changed 
the lives of over two million patients (AOCD).  
Despite the remarkable success, the significant dangers must not be overlooked. 
Measures have been put in place such as a Black Box warning, categorization as 
Category X pregnancy risk, and the REMS program “iPLEDGE”, but significant adverse 
events and pregnancy issues continue to be reported. Regulatory history and extreme 
legal backlash quickly caused the brand-name Accutane by Hoffmann-La Roche to be 
taken off the market, but numerous isotretinoin generic formulations continue to be 
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profitable and prescribed to patients daily. Although many still confuse isotretinoin drugs 
and refer to all of these medications as “Accutane”, this drug is no longer distributed or 
prescribed. When a patient says they are taking “Accutane”, they are most likely 
receiving an isotretinoin drug almost identical to Accutane, but produced by a different 
company. The household name recognition that Accutane achieved after litigation 
remains in dermatological vocabulary although it has been discontinued.   
The REMS of isotretinoin aims to (1) to prevent fetal exposure and (2) to inform 
prescribers, pharmacists, and patients about isotretinoin’s serious risks and safe-use 
conditions (FDA). The stringent regulations of this drug and its implications on the 
pharmacological safety environment warrants scrutinous evaluation and review. How has 
the FDA, the pharmaceutical industry, and the healthcare industry, in general, responded 
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INTRODUCTION TO ISOTRETINOIN (ACCUTANE®) 
 
Introduction  
Isotretinoin, the oral acne medication more commonly known by the former brand 
name Accutane, has been a miracle acne medication for numerous patients, but not 
without significant side effects. Its unmatched efficacy comes with serious questions 
regarding its safety. This medication approved for marketing in 1982 fights “severe 
recalcitrant nodular acne” (Roche Laboratories Inc.). This critical statement is repeated 
numerous times throughout the Accutane package insert and holds a very particular 
meaning upon examination. This particular form of acne culminates in the presence of 
numerous, inflamed nodes that are usually larger than 5 millimeters. In the package insert 
it notes that this medication “should be reserved for patients with severe nodular acne 
who are unresponsive to conventional therapy, including systemic antibiotics” (Roche 
Laboratories Inc.). In other words, this medication is withheld only for patients -who 
have already completed altogether unsuccessful or perhaps minimally successful months 
to years of topical acne treatments, antibiotic courses, or other dermatological treatments. 
This drug should by no means serve as a first-line acne medication. Once the patient has 
proven to be unresponsive to these other treatments, their doctor may talk to them about 
starting isotretinoin oral capsules.  
The side effects of this medicine are far-reaching and can include dermatological 
implications, psychiatric diagnoses, gastrointestinal complications, skeletal issues, and 
other adverse events troubling other systems of the body. Incontestably, the drug’s 
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intense efficacy affects body systems other than the integumentary system alone. The 
extremely high risk for severe birth defects is a huge aspect within precautions of the 
drug and warrants a Black Box warning from the United States Food and Drug 
Administration (FDA).  
Due to the significant side effects and Black Box warning, Accutane and its 
equivalents were eventually required to be dispensed only under a special restricted 
distribution program called iPLEDGE. The prescriber, patient, and pharmacist must meet 
the monthly required interactions of the program to be able to access the drug. This is a 
form of a Risk Evaluation and Mitigations Strategy (REMS) plan as specified by the 
FDA. The goals as stated on the Food and Drug Administration’s website states that the 
goals of the isotretinoin risk evaluation and mitigation strategy are to prevent fetal 
exposure to isotretinoin and to inform prescribers, pharmacists, and patients about 
isotretinoin’s serious risks and safe-use conditions (FDA).  
Data Acquisition 
As an in-depth review, this thesis required numerous sources from primary and 
secondary literature. The package inserts of the isotretinoin drugs are thorough and 
provided ample information about the pharmacologic properties of the drug along with 
lengthy descriptions of potential adverse events. The FDA REMS website provided up-
to-date information regarding specific isotretinoin REMS goals. The iPledge website and 
materials served to explain the program and its goals. There are numerous published 
explanations of sections of Hoffmann-La Roche history, and I used many of these sources 
to create a timeline of the regulatory history. I read through numerous efficacy studies 
and published clinical trials regarding safe-use conditions. I also explored the 
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pharmacology of birth defects more as my topic developed, as this proved to be an 
interesting area of pharmacy that I am excited to learn more about.  
As a personal anecdote, I was able to travel to Boston with the Honors College 
Junior Quest program to interview professionals with potential insight on my topic. I met 
with Dr. Kesselheim, who sparked my interests in the specific area of study into the 
iPledge program more particularly with regards to birth defects. This was when I began 
to switch my study focus from more of the lawsuit and litigation history to the specific 
goals and pharmacological implications of isotretinoin REMS. With all of my collected 
sources and personal experience, I produced my thorough case-study and in-depth review 
of Accutane.  
What is Isotretinoin (Accutane)?  
Isotretinoin is a retinoid drug that works to fight acne by inhibiting sebaceous 
gland function and keratinization (Leyden, et al.). Acne vulgaris is a “chronic 
inflammatory disease of pilosebaceous follicles commonly affecting adolescents and 
young adults” (On, et.al.). The disease pathogenesis of acne is “multifactorial, caused by 
a combination of follicular hyperkeratinization, sebum production, Propionibacterium 
acnes (P. acnes) colonization, and inflammation” (On, et al.). Acne affects patients of all 
ages and ethnicities. While isotretinoin is supposedly withheld for patients displaying 
severe recalcitrant nodular acne, this definition provides blurry standards. It is ultimately 
up to the discretion of the dermatologist and patient to determine the next step of their 
journey to clear skin. It has been brought to attention that in current practice, off-label 
uses include only moderate acne, as well as high-risk neuroblastoma, rosacea, and 
psoriasis (Leyden, et al). Isotretinoin treats acne caused by “androgen stimulation of 
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sebaceous glands leads [which] leads to an increase in sebum, which provides a favorable 
environment for P. acnes' growth” (On, et al.). What makes isotretinoin unique is that it 
treats not only one, but all of the top four most common causes of acne in the same oral 
dosage form.  
Figure 1 shows the chemical structure of isotretinoin. Chemically, it is a 13-cis-
retinoic acid. This active ingredient is related to retinoic acid and retinol (Vitamin A).  
 
 





The ingredient description is described below.  
Active Ingredient: Isotretinoin  
Inactive Ingredients: beeswax, butylated hydroxyanisole, edetate disodium, 
hydrogenated soybean oil flakes, hydrogenated vegetable oil, and soybean oil.  
Chemical formula: C20H28O2 
IUPAC name: (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-
2,4,6,8-tetraenoic acid (Lexicomp) 
 
Pharmacology 
The isotretinoin package insert states that “the exact mechanism of action of 
isotretinoin is unknown'' (FDA). Isotretinoin is relatively water-soluble and metabolized 
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by the cytochrome P450 liver enzyme into active metabolite 4‐oxo‐isotretinoin. 
Isotretinoin acts as a “pro‐drug… converted into five major active metabolites (13‐cis‐4‐
oxo‐retinoic acid/4‐oxo‐isotretinoin, all‐trans‐retinoic acid/tretinoin, all‐trans‐4‐oxo‐
retinoic acid/4‐oxo‐tretinoin, 9‐cis‐retinoic acid, and 9‐cis‐4‐oxo‐retinoic acid)” (Layton). 
These isomerize and bind to the alpha and gamma retinoic acid receptors (RARs) to 
“exert its anti‐proliferative effect on sebocytes, consequently inhibiting cell 
differentiation, sebum secretion, and sebaceous gland size” (On, et al.). The maximum 
plasma concentration of isotretinoin is reached within 4-6 hours, and the peak of 4‐oxo‐
isotretinoin is reached in 6-20 hours (Khoo). The duration and intensity of the dosage for 
this medication varies based on the individual patient case.  
The decrease in sebum secretion is temporary and related to the decrease in 
sebaceous gland size. The differentiation of various sebaceous gland cells is inhibited 
during the isotretinoin therapy as well (Layton).  
The package insert for Accutane recommends 0.5 to 1.0 mg/kg/day given in two 
divided doses with food for 15 to 20 weeks or until cumulative drug levels have been 
reached (Roche Laboratories, Inc). “The accepted target treatment goal is a cumulative 
dose of 120-150mg/kg, with a typical dosing of 0.5mg/kg for the first month, followed by 
1mg/kg thereafter” (Zeichner). An important part of the dosing recommendations is the 
weight-based dosing regimen. Proper body weight should be recorded at initiation of 





Table 1: Isotretinoin Dosing by Body Weight (Based in Administration with Food) 
Body Weight Total mg/day 
Kilograms Pounds  0.5 mg/kg 1 mg/kg 2 mg/kg 
40 88 20 40 80 
59 110 25 50 100 
60 132 30 60 120 
70 154 35 70 140 
80 176 40 80 160 
90 198 45 90 180 
100 220 50 100 200 
 
 
In an example calculation of dosage, a female patient weighs 154 pounds. Her 
dermatologist suggests the less aggressive dosage of treatment and prescribes 1 
mg/kg/day. Her lab tests come in as required, and all relevant parties complete their 






 Absorption, Distribution, Metabolism, and Elimination are the constructs of 
pharmacokinetics. Absorption is influenced by the administration with a high-fat content 
meal (Colburn, et al). The high lipophilicity of isotretinoin means that this drug is well-
absorbed through the membrane, but absorption is enhanced if high-fat meal is 
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concurrently being absorbed (Lexicomp). Safe-use conditions evaluate more studies 
behind the proper use of the drug to ensure most efficient absorption and highest success 
rate for therapy. A second round of isotretinoin therapy is not unheard of, but should aim 
to be avoided by reaching the proper cumulative dose in the first round of the medication.  
Plasma protein, albumin, is responsible for the distribution of more that ninety-
nine percent of isotretinoin. Isotretinoin acts like a prodrug. It is metabolized into 
different metabolites, 4-oxo-tretinoin being the most pharmacologically active 
(Lexicomp). P450 enzymes responsible for the metabolism of this drug include 2C8, 
2C9, 3A4, and 2B6. Isotretinoin is excreted in the urine and feces equally.  
Therapeutics 
Indications determined by isotretinoin manufacturers typically describe severe 
nodular recalcitrant acne. It is deemed and reported that isotretinoin is most commonly 
prescribed off-label for treatment of moderate acne vulgaris.  
Drug Interactions 
Vitamin A, tetracycline antibiotics, and micro-dosed progesterone are among 
proven drug interactions with isotretinoin (Lexicomp). St. John's Wort also may work 
against the efficacy of co-administered birth control methods. Corticosteroid medications 
and Dilantin® (phenytoin) efficacy may also be affected while taking isotretinoin 
medication (FDA medication guide).  
Overview of Side Effects and Adverse Events  




Table 2: Isotretinoin Side Effects and Adverse Events 
Dermatological  Dry, cracked, peeling skin 
 
Dry lips / dry mouth  
 
Rash, skin infection  
 
Extremely sun-sensitive skin  
Skeletal  Muscle aches, joint pain, back pain 
 
Tenderness of the bones (decrease in bone mineral 
density)  
 
Hyperostosis and calcification of ligaments and 
tendons  
 
Potential for premature epiphyseal closure 
Gastrointestinal  Possible upset stomach  
 
Inflammatory bowel disease (regional ileitis)  
Pseudotumor Cerebri 
(Neurological) 
Benign intracranial hypertension  
(associated with concomitant use of tetracyclines) 






Aggressive and/or violent behaviors 
Other  Dry eyes and visual impairment 
 
Corneal opacities  
 
Decreased night vision  
 
Dry nose that may lead to nosebleeds  
 
Acute pancreatitis in patients with elevated serum 
triglycerides  
 
Possible elevated triglycerides (800 mg/dL) 
 9 
 
Impaired hearing (persistent even discontinuation of 
therapy) 
Black Box Warning Debilitating birth defects  
  (Lexicomp, Yoder, Khoo, Layton)  
 
Dermatological side effects listed in the table above are the most commonly 
recognized side effects regarding isotretinoin. These symptoms are manageable in most 
cases, but can become severe in certain patients. Dry skin is an expected symptom due to 
the mechanism of action of isotretinoin. The reduction of sebaceous glands and therefore 
sebum production causes a shock that the skin takes time to adjust to (Yoder). Symptoms 
of this degree are typically managed by intensive-strength lotions and moisturizers. The 
sun-sensitivity brought on by the drug can be combated by avoiding direct sun exposure 
and applying sunscreen frequently. Patients who do not take these precautions may put 
themselves at risk for damaging acne scarring or burns. The skin dryness and 
dermatological side effects are typically the worst during the first two to three weeks of 
treatment (Khoo).  
 The skeletal symptoms caused by the drug are typically not debilitating, but 
should not be ignored. Joint pain, muscle aches, muscle stiffness, or muscle weakness can 
be expected, but medication should be discontinued if these become extreme (Layton).  
 Psychiatric side effects may include depressive thoughts or even suicidal thoughts 
or actions (Lexicomp). Mental health and isotretinoin treatment have brought up rising 
concern of association with suicidal events. Acne treatment is an area of medicine that is 
commonly associated with psychiatric struggles. Especially for Accutane patients, the 
road to clear and healed skin may take the course of numerous years.   
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 Birth defects resulting from fetal exposure of isotretinoin include “abnormalities 
of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus 
and parathyroid glands” (iPLEDGE). A misshaped skull is depicted in Figure 2 below. 
Babies exposed to isotretinoin also are reported to have IQ scores of less than 85. 
Alongside the risk of birth defects, there is also a risk of spontaneous abortion or 
premature births (iPLEDGE).  
 



































THE BLEMISHED HISTORY OF ACCUTANE® 
Development and Discovery 
Accutane’s basic compound is first noted in scientific literature under the 
research of Dr. Werner Bollag of Roche laboratories in Switzerland during the 1960’s 
(Green). The drug, originally tested for its potential efficacy against skin cancers, 
provided potency against cystic acne that was worthy of further pursuit. As many 
medications commonly are discovered, isotretinoin was not originally researched for the 
treatment of acne. This compound was clinically studied for treatments of 
dermatologically orphan diseases or other far-reaching skin conditions. Researchers 
conducting these trials all noted significantly clearer skin of their patients after treatment 
with isotretinoin. This remarkably potent compound, noted as a vitamin A derivative, was 
suspected to be a possible danger to pregnant women. The famous thalidomide crisis of 
the late 1960’s had brought teratogenic drugs and their significant hazards to the forefront 
of society’s conscience. “At that time [the 1970s], in the psychological climate 
engendered by the thalidomide tragedy, it would be inconceivable to develop an agent 
with teratogenic properties for the treatment of such a common complaint as acne” 
(Green).  
This 13-cis-retanoic acid was also under development by two scientists at the 
National Institutes of Health (NIH), Dr. Frank Yoder and Dr. Gary Peck. Peck and Yoder 
hurriedly published news of their groundbreaking acne cure in the Lancet, a British 
medical journal, on November 27, 1976 (Franz). Miscommunication between the NIH 
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researchers and the Swiss Dr. Bollag led to unresolved ambiguity on the identification of 
the true discoverer.  
Premarketing Studies 
Isotretinoin underwent rigorous clinical research studies as “Accutane” under 
Hoffmann-La Roche. Animal studies concluded significant deformities and defects in 
offspring, which secured Accutane’s placement as a potent and potentially teratogenic 
drug. No documented studies were conducted on pregnant women, so the true extent of 
the fetal abnormalities was unknown. Trials in pregnant women spark controversy and 
prove to be difficult to approach properly. The premarket approval process outlined in the 
table above can take numerous years. Roche submitted Accutane for FDA approval in 
July 1981 (Green). The clinical research data was presented to the Dermatologic Drugs 
Advisory Committee panel of specialists. This approval process approach is common 
among new medications, because this smaller committee is more knowledgeable in 
regards to dermatological medications. This committee suggested that Accutane be 
approved for market finally in January of 1982 under contingencies that the label include 
stricter pregnancy warnings. Rather than a pregnancy risk of category C, FDA ordered 
Accutane to be approved under pregnancy warning category X (Green). This changed 
the labelling as “studies have shown an adverse effect on the fetus and there are no 
adequate and well-controlled studies in humans” to “studies in animals or humans have 
demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk 
based on adverse reaction data from investigational or marketing experience” (FDA).  
The controversy shadowing this stipulation was that Hoffman-La Roche only 
tested female participants who were given contraceptives, and the one woman who did 
 13 
become pregnant aborted (Green). The company sharply noted that they did not have 
influence in this abortion against accusations of coercion. As explained, the original label 
noted that no evidence proved the sure cause of birth defects in humans, while no data 
had actually proven this. Nine months after application submission, Accutane® was 
officially FDA-approved.  
Early Years of Marketing 
After the drug was first approved in 1982, obstacles quickly stacked against the 
manufacturing company Hoffmann-La Roche. The 1A, top priority, fast track approval 
medication surprised the company and required four additional months before the official 
launch in the United States in September 1982. Over 200,000 prescriptions for Accutane 
were written in only the first six months (Green).   
As the popularity of the drug grew exponentially, the rising concerns of potential 
toxicity rose as well. Researchers and prescribers across the country began to voice 
concerns for potential birth defects, and some of these concerns were published in 
esteemed journals. Even Dr. Yoder of NIH, the drug’s discoverer, “wrote a letter to 
JAMA in January 1983 to ''express [his] concern and anxiety over the potential tragedy 
that might arise from abuse and misuse of Accutane…the potential toxicity of this drug 
has been seriously under-emphasized” (Yoder). Hoffmann-La Roche received many 
notes of caution and backlash, but continued manufacturing the drug with no alterations. 
The company released its first “Dear Doctor” letter of warning exactly nine months after 
the medication’s release (Green). A “Dear Doctor” letter is formally known now as a 
“Dear Healthcare Provider” letter, or DHCP (FDA). These letters are “correspondence ― 
often in the form of a mass mailing from the manufacturer or distributor of a human drug 
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or biologic or from FDA ― intended to alert physicians and other health care providers 
about important new or updated information regarding a human drug or biologic” (FDA). 
This letter of caution was quickly followed by the distribution of red warning stickers and 
a second Dear Doctor letter. The Accutane label was adjusted to include more details 
warning against the use of the medication in pregnant women (Petrocelli). The 
Dermatologic Drug Advisory Committee revisited Accutane’s regulation to conclude 
Roche’s need to establish strong warnings on the risk of birth defects. Other implications 
followed. The JAMA published a “Medical Directors Page” to advise doctors prescribing 
the drug to use proper precaution. Blood banks were also instructed to refuse donations 
from Accutane patients, as the medication in their circulation could possibly interact 
with a pregnant woman if she receives the transfusion.  
Furthermore in 1984, a “black box” warning was assigned to the Accutane drug 
with regards to the potentially debilitating birth defects. In 1998, more issues regarding 
Accutane’s psychiatric side effects were brought to the attention of physicians and the 
FDA. Depression, psychosis, and possible suicidal thoughts were linked to Accutane 
through many different studies. The package label for Accutane was updated to include 
warnings for these possible adverse events, and prescribers were notified to monitor their 
patients using the medication. Starting in 2000, the prescription could not be filled until 
the monthly negative pregnancy test was completed, which was helpful in part to reduce 
the numbers of birth defect adverse event occurrences. 2001 marked a year of furthering 
patient education and compliance. A clearer medication guide was distributed to patients 
via pharmacists. Hoffmann-La Roche starts the SMART (System to Manage Accutane 
Related Teratogenicity) program (Fain, et al). More and more adverse events came to the 
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FDA’s attention via the Adverse Event Reporting system. After over 6,000 reports of 
psychiatric events, the officials at FDA decided to work with leaders at the National 
Institute of Mental Health and called for more research on retinoid’s effects on the 
Central Nervous System. Hoffmann-La Roche started to include a Medication Guide in 
the Accutane pack. This same year, 2002, the original patent for Accutane expired, and 
FDA approved Amnesteem as the first generic version of isotretinoin. After 20 years on 
the market, over 23,000 reports in the FDA Adverse Reporting System showed that the 
top five events reported were alopecia (hair loss), depression, headache, dry skin, and 
induced abortion purposely to end a pregnancy. The generic drug brands of isotretinoin 
develop individual programs for pregnancy prevention. The FDA Joint Advisory 
Committee and all of the isotretinoin producers eventually agree to link a pregnancy test 
with each monthly prescription.  
Increased Regulation 
A huge mark in the history of Accutane and isotretinoin generics was the 
development of the iPLEDGE program. Wholesalers, pharmacies, and prescribers started 
to register for this program in September 2005. Patients did not register for the program 
until December 30th of 2005. In March of 2006, iPLEDGE further progressed to require 
the iPLEDGE pharmacies to obtain iPLEDGE system authorization before dispensing the 
prescription. A designated Responsible Site Pharmacist is responsible the “point of 
contact for the pharmacy and the iPLEDGE program” (iPLEDGE). Figure 3 illustrates 









The End of Accutane® 
 Despite increased protections for patients taking Accutane®, the severe adverse 
events became too much to bear for Roche and it’s Accutane® brand. In 2009, Roche 
withdrew Accutane® from its United States market, contrary to popular assumptions that 
the FDA pulled Accutane® from the market. It is presumed that Roche pulled its drug as a 
result of safety issues, declining sales, loss of market share, lawsuit losses, or most likely 
a combination of all four (Lamb). The following announcement was made on June 26, 
2009: 
“Roche Holding AG, the world’s biggest maker of cancer drugs, is pulling its 
Accutane acne medicine from the U.S. market after juries awarded at least $33 
million in damages to users who blamed the drug for bowel disease. 
 
Roche notified the U.S. Food and Drug Administration today that it was 
withdrawing Accutane after a “reevaluation” of its product lines showed it faced 
serious challenges from generic competitors, company officials said in a statement. 
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“In addition, Roche has been faced with high costs from personal-injury lawsuits 
that the company continues to defend vigorously,” according to the statement. 
 
About 13 million people have taken Accutane since it went on the market in 1982. 
The medication was Roche’s second-biggest selling drug before the patent expired 
in 2002 and rivals started selling generic versions. Roche’s prescription market 
share of the drug is now below 5 percent, the company said.” (Lamb) 
  
Roche still markets isotretinoin as Roaccutane® in Europe. Many other generics 
are still available under names such as Absorica, Amnesteem, Sotret, Myorisan, and 
Zenatane, some of which were approved even after the withdrawal of branded Accutane®. 
Table 3, below, summarizes these isotretinoin drugs remaining on the market. 
 
Table 3: Drug Name and Date of Market Entry 
Drug Name Labeler Entry Into Market 
1982 – FDA Approval of Accutane 
Amnesteem Mylan Pharmaceuticals, Inc. 11/11/2002 
Claravis Teva Pharmaceuticals USA, Inc. 05/09/2003 
2009 – Roche Withdrawal of Accutane 
Myorisan Akorn, Inc. 05/01/2012 
Absorica Sun Pharmaceutical Industries, Inc. 06/08/2012 









CURRENT REGULATION OF ISOTRETINOIN 
 Given the compromised safety profile of isotretinoin, the FDA has established 
number safeguards for patients on the medication. Those include setting dispensing 
program requirements through the FDA REMS program for isotretinoin called 
“iPLEDGE”, as well as black box warnings on their package insert, which specifically 
seeks to prevent fetal exposure through special dispensing requirements. 
Risk Evaluation and Mitigation Strategies (REMS) and Applications to Isotretinoin 
Prescription drugs on the market often come with numerous side effects ranging 
from minor to life-threatening. The benefit of the medication in some cases may 
outweigh the risks, so it is necessary for these drugs to pass the proper approval process. 
On September 27, 2007, the Food and Drug Administration (FDA) passed an 
Amendments Act that formally created a program of Risk Evaluation and Mitigation 
Strategies (REMS) for the approval of these high-risk drugs (FDA). This gives FDA the 
critical authority to require the manufacturer to outline and ensure that the potential 
benefit of their medication outweighs the risks. This program gave officials a mechanism 
to get drugs approved despite very focused safety concerns. They may have been more 
inclined to reject these kinds of drug applications in the past. The US FDA website 
published that there are currently 60 approved REMS (FDA). Each REMS report 
includes detailed information including product name, new drug application (NDA) or 
abbreviated new drug application (ANDA) application number, application holder, and 
the date that the REMS was added to the database.  
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REMS can be categorized as “elements to assure safe use (ETASU)”, 
“communication plan”, or “medication guide”. Below is a table that includes descriptions 
for the categories.  
Table 4: REMS Categories 
Elements to assure 
safe use (ETASU) 
Typically require clinicians or healthcare settings to become 
certified prior to prescribing and to participate in additional 
REMS activities, such as training, patient counseling, and 
monitoring 
Communication plan  Typically composed of letters, website, and facts sheets 
describing the specific safety risks identified in the REMS 
Medication guide REMS element typically included as part of their labeling  
(FDA) 
REMS data files are routinely monitored and modified. Currently 49 (82%) of the 
REMS include ETASU. 7 (12%) include only a communication plan. 4 (6%) include only 
the medication guide. Very commonly, REMS will include more than one of these 
elements (FDA).  
It is up to the FDA and manufacturer to monitor if the REMS report is being 
properly followed to prevent these adverse effects. This has been an ambiguous task and 
proves to be difficult to assess. Adverse events can be reported in databases such as 
“AERS” (Adverse Event Reporting System), but monitoring continually proves difficult. 
Multiple studies, including Kevin Fain and G. Caleb Alexander’s study of “Are Food and 
Drug Administration prescription drug safety plans working? A case study of 
isotretinoin”, study the effectiveness of REMS (Fain, et al.). The study brings to light the 
fact that “numerous studies have evaluated the impact of FDA regulatory 
communications, [but] far less is known about the more recently implemented REMS 
program” (Fain, et al). A case study on isotretinoin in particular showed “the median 
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proportion of concomitant use of contraception with isotretinoin was 29%, which 
increased an absolute 1.3% during the 24 months after iPLEDGE implementation” (Fain, 
et al). This minor increase was concerning to researchers who had predicted a larger 
increase. The FDA’s top priority is to ensure the safety of public health by monitoring 
drugs among other food and cosmetic products.  
Black Box Labeling and Applications to Isotretinoin 
 A Black Box warning is the FDA’s most urgent labeling system on a prescription 
package (Wagner, et al.). This boxed warning serves as a way to remind patients of the 
dangers of common adverse or potentially life-threatening adverse events. In a literal 
sense, a black box warning is a printed warning on promotional materials or medication 
guides that outline the adverse reactions you may experience during or after use 
(Weyant). A Black Box prescription typically comes paired with a risk mitigation 
strategy or other resources exceeding the base-level adverse event monitoring system. For 
example, Accutane, and currently, isotretinoin, comes with a black box warning of 
severe birth defects and warned females to not get pregnant while taking this medication.  
Mitigating Fetal Exposure 
The first major component of the REMS of this medication is to prevent fetal 
exposure. Accutane  has great potential to cause debilitating birth defects, so the 
manufacturing company must take effective preventative measures. The teratogenic drug 
characteristics, pharmacokinetics of pregnant women, and proper categorization of 
pregnancy medications are crucial parts to this detailed risk evaluation and mitigation 
strategy. 
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As previously stated, Accutane® and isotretinoin generics are highly teratogenic 
compounds. A teratogen is broadly defined as a drug that has the potential to cause birth 
defects. Teratogenic drugs may cross into the developing fetus’s blood supply via the 
mother's blood. The the transfer of blood from the mother to the placenta is illustrated. 
This transfer of blood carries all of the mother’s important nutrients, gases, antibodies, 
and other molecules. Unfortunately, the mother’s metabolism and ability to excrete 
harmful substances is much further developed than the unborn babies. This explains why 
pregnant women must closely monitor their intake of toxic substances, medications, and 
potentially harmful metabolites.  
Drugs cross into the fetal blood supply via passive diffusion, facilitated diffusion, 
and active transport (Gunatilake). This indicates that mainly freely unbound drugs cross 
the placenta. As isotretinoin is a fat-soluble drug, the active metabolites easily cross over 
into the placenta. This harmfully affects development in numerous organ systems, 
especially the central nervous system, cardiovascular system, and endocrine system. In 
some cases, isotretinoin’s teratogenicity and high potency may cause spontaneous 
abortions.  
Broadly, birth defects may range in severity due to the variety of dose, gestational 
age at the time of exposure, and type of drug (Gunatilake). Higher doses of certain 
teratogenic medications may be discontinued if possible or lowered dose prescribed to 
minimize fetal toxicity. As a pregnant woman’s blood plasma volume increases by thirty 
to fifty percent (Sachdeva, et al) and many other pharmacokinetic factors are altered, 
distribution of drug in maternal blood stream may vary widely. There is an increase in 
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body fat during pregnancy as well. This indicates that fat soluble drugs will be distributed 
to a greater volume which may have a more widespread potency (Gunatilake).  
Furthermore, the gestational age at the time of drug exposure is also critical to the 
risk of birth defects. The fetal development is culminated in forty weeks. This time period 
can also be categorized into three trimesters. Women who are planning to become 
pregnant are typically advised to withdraw their unnecessary medication usage three to 
six months before conception. Drugs or harmful substances can remain within the 
mother’s blood system for various ranges of time, but it is safer to ensure that drugs will 
not be transferred to the baby after conception. The early days and weeks following 
conception are crucial periods of development.  Within the first two weeks after 
conception, the drugs cause an “all-or-nothing effect” (Gunatilake). Some women may 
not know that they are pregnant during this time and may not have discontinued harmful 
medications. The fertilized egg may not implant properly, spontaneous abortion may 
occur in early pregnancy, or the drug may have no effect. In three to eight weeks after 
fertilization the fetal organs are developing in a stage called organogenesis. During this 
stage, the baby is most susceptible to birth defects. In the second and third trimesters, 
fetal development is majorly growth and maturation. Since primary organ development is 
complete, drugs are unlikely to cause obvious birth defects.  
The type of drug plays a vital part in the potential for birth defects. Examples of 
commonly used drugs that are teratogenic include Angiotensin Converting Enzyme 
(ACE) inhibitors, thalidomide, warfarin, male hormones, some anticonvulsant 
medications, high doses of Vitamin A, and numerous others (Sachdeva, et al.). Pregnancy 
poses a unique physiological state and pharmacology of all medications. The Food and 
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Drug Administration recognizes that total avoidance of all drugs or medications may be 
unfeasible for many patients. Certain women may require medication for chronic disease 
management such as asthma, epilepsy, hypertension, or psychiatric conditions (Sachdeva, 
et al). In addition to certain chronic conditions, some women develop acute conditions 
that require pharmacological intervention during gestation. Gestational diabetes, 
exacerbated migraine symptoms, high blood pressure related to pregnancy, anemia, or 
various infections can occur during pregnancy and must be treated (Sachdeva, et al). 
The FDA has created a categorization for various drugs used in pregnancy in 
1979. As a result of the thalidomide crisis in the late 1960’s, many pregnant women were 
delivering babies with congenital abnormalities including phocomelia, a condition that 
involves the malformation of the arms and legs. This refined system developed rankings 
for teratogenic risk. The categories A, B, C, D, and X outline the level of risk associated 













Table 5: Pregnancy Categories and Description 
Category A Adequate and well-controlled studies have failed to demonstrate a risk 
to the fetus in the first trimester of pregnancy (and there is no evidence 
of risk in later trimesters) 
Category B Animal reproduction studies have failed to demonstrate a risk to the 
fetus and there are no adequate and well-controlled studies in pregnant 
women 
Category C Animal reproduction studies have shown an adverse effect on the fetus 
and there are no adequate and well-controlled studies in humans, but 
potential benefits may warrant use of the drug in pregnant women 
despite the potential risks 
Category D There is positive evidence of human fetal risk based on adverse 
reaction data from investigational or marketing experience or studies 
in humans, but potential benefits may warrant use of the drug in 
pregnant women despite potential risks 
Category X Studies in animals or humans have demonstrated fetal abnormalities 
and/or there is positive evidence of human fetal risk based on adverse 
reaction data from investigational or marketing experience, and the 
risks involved in use of the drug in pregnant women clearly outweigh 
potential benefits.  
(US Department of Health and Human Services) 
The table below lists examples of commonly prescribed medications within each 
category.  
Table 6: Pregnancy Category Examples 
Category A Vitamins B, C, D, E, folic acid 
Category B acetaminophen, amoxicillin 
Category C Antimalarials, antifungals, gentamicin, aspirin 
Category D Tetracyclines, streptomycin, ACE inhibitors 
Category X Androgens, estrogens, bronchodilators, thalidomide, oral 
contraceptives, statins  
(FDA) 
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Specifically pertaining to isotretinoin, pregnancy precautions have been very 
closely considered and monitored. Isotretinoin is given both a Black Box pregnancy 
warning and Category X pregnancy medication rating. Manufacturers are required per 
their REMS agreement to ensure that patients are properly informed and measures are 
taken to prevent fetal exposure.  
Dispensing Requirements 
Accutane, as a high-risk drug, has numerous stringent dispensing requirements 
in place in order to increase proper safety of the medication. A patient cannot simply get 
prescribed Isotretinoin and go to receive their prescription. The “iPLEDGE” program was 
developed as a strategy to further prevent pregnancy while completing isotretinoin 















Table 7: Monthly Required iPLEDGE Interactions 
 
 
Female patients of 
childbearing potential  
Male patients, and female 




Confirms patient counseling x x 
Enters the 2 contraception 
































Table 8: Laboratory Requirements for Isotretinoin Prescription Monitoring 
Pregnancy tests TWO negative urine or serum pregnancy tests 
First “screening” test: obtained by prescriber  
Second “confirmation” test: CLIA certified laboratory at 
least 19 days after first test 
• During first 5 days of menstrual period preceding 
start of therapy   
Lipids Monitor for hypertriglyceridemia  
Liver function tests Monitor for elevation of liver enzymes  
Glucose Monitor for problems controlling blood glucose 
Creatinine Phosphokinase 
(CPK) 
Monitor for elevated levels of enzyme suggesting 




All patients must comply with iPLEDGE stipulations in order to receive their 
prescription. The following conditions must be met: 
• Must be registered with iPLEDGE program by the prescriber 
• Must understand that severe birth defects can occur with use of isotretinoin by 
female patients 
• Must be reliable in understanding and carrying out instructions 
• Must sign a patient information/ informed consent 
• Must fill and pick up prescription within 7 days of specimen collection 
(female/childbearing potential) 
• Must fill and pick up prescription within 30 days of office visit (male 
patients/non-childbearing potential)  
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• Must not donate blood while on isotretinoin and for one month after treatment 
cessation  
• Must not share isotretinoin with anyone (FDA medication guide) 
As discussed, strict prescribing rules require two forms of birth control and 
monthly blood monitoring including pregnancy tests. Commitment to abstinence can 
allow patients to avoid two forms of birth control Table 9 below outlines the primary and 
secondary forms of contraception outlined on the iPLEDGE website.  
 
Table 9: Acceptable Primary and Secondary Forms of Birth Control 
Primary forms of Birth Control 
Implantable Hormones Hormonal IUD 
Partners Vasectomy Tubal Sterilization  
Non-Hormonal IUD Hormonal Injection 
Hormonal transdermal patch Hormonal Vaginal Ring 




Secondary Forms of Birth Control 
Male Latex Condom Cervical Cap 
Diaphragm Cervical Sponge 
 
Safe Use Conditions 
Isotretinoin is advised to be administered with meals. Numerous case studies have 
proven that the oral absorption of isotretinoin is beneficially maximized when given with 
a high-fat meal. A crossover study of 74 healthy adult subjects receiving an 80 mg oral 
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dose compared the AUC of fasted and fed conditions. Both peak plasma concentration 
and area under the curve of the active ingredient more than doubled following a high-fat 
meal. A “high fat” is defined by the FDA “as [fat making up] 50 percent of total caloric 
intake of the meal” (Zeichner). High-fat ingredient suggestions include fatty fish like 
salmon, avocados, extra virgin olive oils, and cheeses. Many prescribers are not properly 
educating their patients on the proper safe-use techniques. This may lead to unsuccessful 
treatment and a need for a second round of isotretinoin therapy. The generic Absorica is 
the first to provide the same efficacy with or without a meal. 
 An open randomized crossover design study of twenty males also concluded that 
“coadministration of isotretinoin with food may be the best method of administration” 
(Wayne, et al). Isotretinoin blood concentrations determined by an HPLC method 
supported prior publications suggesting the increased bioavailability with food within a 
one-hour window of oral administration (Wayne, et al.). The relative bioavailability 
(AUC) of these subjects was found to be about two times higher when medication was 
“taken one hour before, concomitantly with, or one hour after a meal” (Colburn, et al.).  
 The responsibility of safe-use suggestions falls in the hands of the prescribing 
practitioners and dispensing pharmacists. In order to dispense isotretinoin, pharmacies 
must be registered and certified through the iPLEDGE program as active. Similarly, 
dermatologists or other prescribing physicians must complete a training program through 
iPLEDGE in order to be registered to prescribe the drug.  
Patient Adherence 
As outlined in the iPLEDGE regulations, the prescriber, pharmacist, and patient 
must all complete the required steps within the specified time frame. Strenuous 
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circumstances or undue hardship may lead to patient noncompliance. Failure to fill 
prescription on time may lead to an inefficient dosing schedule and decreased efficacy of 
the isotretinoin course. Under-dosing and patient noncompliance are common causes of 
relapse or re-treatment. Patient factors for unsuccessful therapy cannot be controlled, but 























Accutane has a rich history of litigation and controversy. The conflict between 
brand-name discoveries and generic liabilities is an ongoing discussion that continues to 
prove difficult to reach a consensus. The FDA, the pharmaceutical industry, and the 
healthcare industry, in general, have responded to high risk drugs (like Accutane) 
through many different pursuits including the establishment of lengthy Risk Evaluation 
and Mitigation Strategies. The REMS of isotretinoin aims to (1) to prevent fetal exposure 
and (2) to inform prescribers, pharmacists, and patients about isotretinoin’s serious risks 
and safe-use conditions (FDA). These strategy’s success and true significance is difficult 
to measure, and I intend to pursue further research on the data behind the success of the 
iPLEDGE program. 
As a current discussion and implication of the COVID-19 public health 
emergency, FDA released a statement stating that it does not plan to punish sponsors that 
fail to adhere to the REMS requirements for certain laboratory testing. This is an 
unprecedented alteration to the REMS requirements as this is a difficult time for our 
general population. For patients currently taking isotretinoin, this means that laboratory 
monitoring requirements will be waived. In addition, pregnancy tests will be completed 
at-home and communicated to the prescribers via telehealth.  
Throughout the process of this thesis, I learned about isotretinoin in great detail. I 
am interested in pursuing research behind other REMS programs and their success rates. 
In my opinion, the iPledge program may not be proving sufficient in protection and 
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prevention of the critical adverse events that isotretinoin can cause. Women are still 
becoming pregnant despite the strict warnings and requirements, and that is problematic! 
Moreover, I started this project with intentions to pursue more of the lawsuits and 
litigation side of Accutane, but learned through my early research that I was much more 
interested in the regulatory side and specific goals of the REMS. The regulatory 
development of this high-risk drug is fascinating as well as its attempt to combat adverse 
events. The two goals of isotretinoin REMS were interesting to explore in further detail. 
In particular, I am very interested in the pharmacology of birth defects and the pregnancy 
categories. Isotretinoin is ranked as category X along with other medications, and I am 
interested in learning more about the other category X medications and what exactly their 
mechanisms of actions are. This broad category of isotretinoin as a whole has led me to 
many new interests in various area of study.  
Accutane’s unsurpassed efficacy is paired with serious risk of adverse events 
and birth defects, which poses ethical questions regarding its safety and necessity. Its 
regulatory history established precedent in Food and Drug Administration Risk 
Evaluation and Mitigation Strategies and brought awareness to the sharp dangers of 
teratogenic drug use. Some question the risk-benefit evaluation of such a toxic drug for 
acne. Accutane and isotretinoin generic drugs have changed the lives of over two 
million patients (AOCD). These drugs will continue to be prescribed and dispensed to 
patients daily, so it is of utmost importance to ensure that these dangerous medications 
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